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Abstract
Background: Autosomal dominant inheritance of congenital nephrogenic diabetes insipidus (CNDI) is rare and
usually caused by variations in the AQP2 gene. We have investigated the genetic and molecular background
underlying symptoms of diabetes insipidus (DI) in a Swedish family with autosomal dominant inheritance of
the condition.
Methods: The proband and her father were subjected to water deprivation testing and direct DNA sequencing
of the coding regions of the AQP2 and AVP genes. Madin-Darby canine kidney (MDCK) cells stably expressing
AQP2 variant proteins were generated by lentiviral gene delivery. Localization of AQP2 variant proteins in the
cells under stimulated and unstimulated conditions was analyzed by means of immunostaining and confocal
laser scanning microscopy. Intracellular trafficking of AQP2 variant proteins was studied using transient expression
of mutant dynamin2-K44A-GFP protein and AQP2 variant protein phosphorylation levels were assessed by
Western blotting analysis.
Results: Clinical and genetic data suggest that the proband and her father suffer from partial nephrogenic DI due to a
variation (g.4807C > T) in the AQP2 gene. The variation results in substitution of arginine-254 to tryptophan (p.R254W)
in AQP2. Analysis of MDCK cells stably expressing AQP2 variant proteins revealed disabled phosphorylation, impaired
trafficking and intracellular accumulation of AQP2-R254W protein. Notably, blocking of the endocytic pathway
demonstrated impairment of AQP2-R254W to reach the cell surface.
Conclusions: Partial CNDI in the Swedish family is caused by an AQP2 variation that seems to disable the encoded
AQP2-R254W protein to reach the subapical vesicle population as well as impairing its phosphorylation at S256. The
AQP2-R254W protein is thus unable to reach the plasma membrane to facilitate AVP mediated urine concentration.
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Background
Congenital nephrogenic diabetes insipidus (CNDI) is a
disorder characterized by polyuria and polydipsia due to
renal resistance to the antidiuretic hormone, arginine
vasopressin (AVP). The majority of cases are caused by
variations in the AVPR2 gene encoding the renal V2
receptor or by autosomal recessively inherited variations
in the AQP2 gene encoding the collecting duct water
channel aquaporin-2 (AQP2) [1]. AQP2 forms tetramers
that are localized to sub-apical vesicles and the apical
plasma membrane in kidney collecting duct principal
cells [2, 3]. Upon AVP stimulation, AQP2 is phosphory-
lated at the C-terminal S256 by Protein Kinase A (PKA)
[4], where after AQP2-containing subapical vesicles are
inserted into the apical plasma membrane, facilitating
AQP2 accumulation and thus, urine concentration.
Evidence suggests that AQP2 constitutively shuttles
between the plasma membrane and subapical vesicles
[5], and that the life-time in the plasma membrane is
determined by phosphorylation at S256 [6, 7]. It has
been shown that AQP2-S256A, which mimics constitu-
tively non-phosphorylated AQP2, accumulates in the
plasma membrane if endocytosis is blocked by express-
ing dominant-negative dynamin-2 [8]. Thus, it seems
that S256 phosphorylation shifts the balance of AQP2
recycling, facilitating AQP2 accumulation in the plasma
membrane. In addition, phosphorylation at S256 on at
least three out of four monomers in the AQP2 tetramer
seems to be necessary for accumulation of AQP2 in the
apical membrane [9–11].
Defective trafficking of AQP2 in response to AVP
stimulation is suggested as the cause of the rare cases of
dominantly inherited CNDI [12, 13] and dominant
inherited variations affecting the PKA consensus site are
suggested to disable phosphorylation at S256 [14, 15]
and consequently, disrupt the kidneys urinary concentra-
tion ability.
Variant AQP2 monomers are further believed to have
a dominant negative effect on wildtype (WT) monomers
resulting in altered trafficking, missorting or retention in
the Golgi apparatus [13, 16–18]. Of special note, the ma-
jority of variations causing dominantly inherited CNDI
are associated with partial diabetes insipidus (DI), where
affected subjects retain an ability to concentrate urine in
response to high levels of AVP or desamino-8-D-argin-
ine vasopressin (dDAVP). This has led to the suggestion
that functional AQP2 tetramers either in the form of
WT homo-tetramers or WT-variant hetero-tetramers
are formed and reaches the apical plasma membrane
[1, 12, 14, 15, 18].
In the present study, we identified a novel g.4807C > T
variation in the AQP2 gene in a Swedish family with dom-
inant inheritance of CNDI. This variation causes substitu-
tion of arginine-254 to tryptophan (AQP2-R254W) in the
C-terminal of AQP2. In order to substantiate that the
variation identified is causal to CNDI in the family and
investigate the underlying mechanism responsible, we
further investigated the cellular handling of the AQP2




The family history was recorded in order to determine
the presence of symptoms of DI in a Swedish family and
a water deprivation test (WDT) was performed accord-
ing to normal clinical practice. Regarding the clinical
tests The Regional Committee on Biomedical Research
Ethics has agreed that ethical approval and consent to
participate was not required. The parents of the patient
granted written informed consent for publication of this
report as the patient was underage.
Gene sequencing
Genomic DNA was extracted from full blood using
QIAamp DNA Blood Mini Kit (Qiagen Nordic,
Copenhagen, Denmark). The coding regions of both
the AVP and the AQP2 gene was amplified by poly-
merase chain reaction and the amplified gene products
was sequenced using BigDye Terminator v1.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA).
Sequencing products was analyzed using ABI Prism
3100 Avant Genetic Analyser (Applied Biosystems).
Cell culture
Polarized Madin-Darby canine kidney (MDCK; catalog
number CCL-34TM, American Type Culture Collection,
Boras, Sweden) cells were used to resemble the collect-
ing ducts in vivo. Cells were cultivated in tissue culture
flasks (TPP, Techno Plastic Products AG, Trasadingen,
Switzerland) in complete Dulbecco's Modified Eagle's
Medium (DMEM) (Gibco, Invitrogen, Taastrup, Denmark)
containing 0.29 mg/ml glutamine (Sigma-Aldrich,
Broendby, Denmark), 0.06 mg/ml penicillin (Farma-Plus,
Oslo, Norway), 0.1 mg/ml streptomycin (Sigma-Aldrich)
and 10 % fetal calf serum (Sigma-Aldrich). The cells were
maintained at 37 °C and 5 % CO2.
Lentiviral production and transduction of MDCK cells
In order to produce MDCK cells stably expressing
AQP2-protein, lentivirus (LV) vectors encoding AQP2-
WT and AQP2-R254W were produced (see below). For
comparison purposes we also generated LVs encoding
AQP2-R254L [14]. The LV vector constructs contain a
phosphoglycerate kinase (PGK) promoter, the AQP2
cDNA (encoding WT, R254W or R254L proteins), an
internal ribosome entry site sequence (IRES) and a se-
quence coding for resistance towards puromycin (puro),
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enabling selection of the transduced cells. A schematic
presentation of the LV construct is depicted in Fig. 3a.
Initially, WT AQP2 cDNA (ImaGenes, Berlin,
Germany) was cloned into pcDNA3.1 vector (Invitro-
gen) using BglII/XhoI and BamHI/XhoI, respectively
(New England Biolabs). The desired mutation was
introduced using Quick Change Site-Directed Muta-
genesis Kit (Stratagene, AH Diagnostics A/S, Aarhus,
Denmark). To generate AQP2 c.760C > T cDNA (corre-
sponding to AQP2 g.4807C > T), encoding R254W
mutant protein, sense primer 5’-gaggtgcgaggtggcagtc
ggtgg-3’ and antisense primer 5’-ccaccgactgccaccgtcg-
cacctc-3’ were used. Underlined bases mark the targets
for the mutagenesis. The AQP2-R254L (GenScript,
New Jersey, USA) was likewise cloned into pcDNA3.1
vector using BglII/XhoI and BamHI/XhoI. The three
AQP2 cDNA sequences were subsequently excised from
the corresponding pcDNA3.1 vectors using PmeI and
XbaI and ligated into the PmeI and XbaI sites of the
pCCL-PGK-Puro plasmid [19]. The resulting LV vectors
were named pLV/PGK-AQP2-WT, pLV/PGK-AQP2-
R254W and pLV/PGK-AQP2-R254L, respectively. Plas-
mid DNA was purified using PlasmidPlus kits (Qiagen
Nordic). Restriction enzyme analysis and DNA sequen-
cing verified all constructs.
LV vectors were generated as previously described
[19, 20]. In brief: On day 1, 1x107 human embryonic
kidney (HEK-293 T; catalog number CRL-3216,
American Type Culture Collection) cells were seeded
in p15 dishes (Greiner, Sigma-Aldrich) containing
complete DMEM (see above). On day 2, a transfection
mix of 7.3 μg pRSV-Rev, 9.1 μg pMD.2G, 31.5 μg
pMDIg/p-RRE, 31.5 μg AQP2 plasmid and 1 μg plas-
mid DNA encoding enhanced green fluorescent pro-
tein (GFP) were prepared for each dish, and the cells
were transfected using calcium phosphate transfec-
tion. On day 3, the medium was replaced with fresh
complete DMEM. On day 4, the supernatant with
virus were harvested and filtered through a 0.45 μm
filter (Millipore A/S, Hellerup, Denmark), and there-
after purified by ultracentrifugation through a sucrose
solution at 25,000 rpm for 2 h. The virus pellet were
resuspended in PBS and stored at -70 °C. Concentra-
tions of the produced lentivirus were determined by
measuring HIV-1 p24 by enzyme-linked immunoassay
(Zeptometrix, Buffalo, NY, USA).
Approximately 8x104 MDCK cells were seeded in 6-
well-plates (TPP) the day before transduction. The
transduction was performed with 40 ng p24/well. The
LVs was added to complete DMEM medium containing
8 μg/mL polybrene (Sigma-Aldrich) and exchanged with
the medium in the plates. Selection with 10 μg/mL
puromycin (Invitrogen) started 72 h post-transduction.
Wells containing untransduced MDCK cells were used
as controls. Comparable fluorescent signals (Fig. 3) and
amounts of total AQP2 protein (Fig. 5c) were identified
in cells transduced with LV vectors encoding AQP2-WT,
AQP2-R254W or AQP2-R254L showing that AQP2 is
similarly expressed in the three cell lines. However, it
should also be mentioned that intercellular variation in
AQP2 expression, most likely representing copy num-
ber differences and/or diverse integration sites as each
of the cell lines was obtained by pooling puromycin
resistant cells, was observed following immunostaining
and CLSM analysis.
Immunostaining and confocal laser scanning microscopy
For investigation of the localization and trafficking of
variant AQP2, immunostaining and confocal laser scan-
ning microscopy (CLSM) experiments were performed.
On day 1, MDCK cells were seeded at confluency on
Transwell polycarbonate membranes (12 mm, 0.4 μm
pore size, Costar, Sigma-Aldrich). After 24 h culture
medium was changed and the cells were treated with the
basal cAMP lowering drug indomethacin (10 μM) over
night. On day 3, the cells were incubated in preheated
PBS-ABC (PBS (Sigma-Aldrich) containing 1 mM CaCl2,
0.5 mM MgCl2) with (150 μM) or without forskolin for
1 h at 37°. Then cells were washed 3x5 min. in PBS-
ABC. Thereafter the cells were fixed in 4 % paraformal-
dehyde (Lillies buffer, Buch & Holm, Herlev, Denmark)
for 5 min. and washed 3x5 min. in PBS-ABC. Prior to
immunostaining the cells were permeabilized with PBS
solution containing 3 % BSA and 0.3 % Triton X-100 for
15 min. at room temperature. The Transwell membranes
were then cut out from their plastic support and sub-
jected to antibody solutions on parafilm.
Primary antibodies (polyclonal goat anti - AQP2 anti-
body, C-17, Santa Cruz Biotechnology, Dallas, Texas,
USA, and polyclonal rabbit anti - ZO-1 antibody, Mid,
Invitrogen) were diluted 1:100 in blocking buffer (BB,
0.5 % (w/v) bovine serum albumin in PBS-ABC) and the
cells were incubated in the solution for 1 h at room
temperature, followed by three washing steps of 5 min.
in PBS. Secondary antibodies (Alexa Fluor® 488 donkey
anti - goat, catalog number A-11055, and Alexa Fluor®
568 polyclonal donkey anti-rabbit, catalog number A-
10042, both Molecular Probes, Invitrogen) were likewise
diluted in BB (1:400), and the cells were incubated in the
solution for 1 h at room temperature. Finally, the cells
were washed 3x5 min. in PBS-ABC before incubated
with 4',6-diamidino-2-phenylindole (DAPI) (Sigma-Al-
drich) for 5 min. Finally, cells were washed 2x5 min. in
PBS and carefully mounted on glass slides using Glycer-
gel (Dako, Glostrup, Denmark) supplemented with 1,4-
Diazabicyclo(2,2,2)octane (2.5 % w/v) (Sigma-Aldrich).
Images of AQP2-WT, AQP2-R254W and AQP2-R254L
were captured on a CLSM (LSM 710, Zeiss, Jena,
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Germany) by using a 488 nm line of a multiline argon
laser (detection of Alexa-488), the 405 nm line of a 405-
430 nm diode laser (detection of DAPI), and an 63 × oil-
immersion objective with a NA of 1.4.
Transfection with plasmid DNA encoding dynamin2-,
Rab7- and Rab9-GFP fusion proteins
Transfections experiments were performed using Lipo-
fectamine 2000 (Invitrogen) following the manufacturer’s
recommendations. MDCK-AQP2-WT, MDCK-AQP2-
R254W and in some cases MDCK-AQP2-R254L cells (as
indicated) were seeded on Transwell polycarbonate
membranes (12 mm, Costar) covered by DMEM without
fetal calf serum.
Endocytosis of AQP2 was investigated by transfecting
the cells with 0.4 μg Dyn2-WT-GFP or 0.4 μg Dyn2-
K44A-GFP plasmid DNA, encoding WT or mutant
dynamin proteins C-terminally fused to GFP, respectively
(Addgene, Cambridge, MA, USA). Upon expression of
the Dyn2-K44A-GFP protein, the dynamin-2-dependent
endocytic pathway is blocked. For localization of late
endosomes, MDCK cells expressing AQP2-WT, AQP2-
R254W or AQP2-R254L were transfected with 0.4 μg
Rab7-GFP and 0.4 μg Rab9-GFP, respectively. The Rab7-
GFP and Rab9-GFP plasmids encodes GFP-tagged vari-
ants of Rab7 [21] and Rab9 [22] involved in retrograde
transport as well as transport between late endosomes
and the trans-Golgi network.
Medium was replaced 6 h and 24 h post-
transfection. Two days after transfection the cells were
fixed in 4 % paraformaldehyde (Buch & Holm) for
5 min. Prior to immunostaining of AQP2 the cells
were permeabilized with PBS solution with 3 % BSA
and 0.3 % Triton X100 for 15 min. A polyclonal
goat anti - AQP2 antibody (C-17, Santa Cruz Biotech-
nology) was used as primary antibody in a 1:100 dilu-
tion. Alexa Fluor® 568 donkey anti - goat, was used as
secondary antibody (1:400, catalog number A-11057,
Molecular Probes). Visualization was performed by
using a 488 nm line of a multiline argon laser (detec-
tion of GFP), the 563 nm line of a helium-neon laser
(detection Alexa-568), the 405 nm line of a 405-
430 nm diode laser (detection of DAPI), and an 63×
oil-immersion objective with a NA of 1.4 on a LSM
710 confocal laser scanning microscopy (Zeiss).
Identification of phosphorylated AQP2 by Western
blotting analysis
On day 1, transduced MDCK-cells were seeded in T25
culture flasks (TPP) at approx. 20 % confluency. On day
2, the medium was exchanged with fresh medium con-
taining indomethacin (10 μM). Day 3: The media was
removed and exchanged with preheated PBS-ABC with
or without forskolin for 1 h (150 μM, Sigma-Aldrich).
The cells were then harvested and centrifuged for 3 min.
at 220 g and the supernatant discharged. Lysis buffer
(50 mM Tris-HCl, 5 mM EDTA, 1 mM DTE, 10 μg/mL
aprotinin, 10 mg/mL soyabean trypsin inhibitor, 1 tablet
Complete mini and 1 % Triton X-100) were added to
the pellet and incubated on ice for 1 h [23]. The samples
were then centrifuged shortly at 10,000 g and protein
concentration was measured on the supernatant fraction
(Bradford Protein Assay, BioRad, Copenhagen,
Denmark). Western blotting analysis was performed as
previously described [23]. In brief, 10 μg total protein
was loaded on a 12 % polyacrylamide gel (Criterion
TGX gel, BioRad) together with a Precision Plus Protein
All Blue Standards marker (BioRad) followed by transfer
to a PVDF midi membrane (BioRad) using the Trans-
Blot TurboTransfer system (BioRad). The membrane
was subsequently cut in three parts before immunolabel-
ing was performed using individual antibodies targeting
AQP2, phosphorylated AQP2 (p-AQP2) [4, 11] and ß-
actin. For detection of AQP2 a primary polyclonal goat
anti - AQP2 antibody (1:500, C-17, Santa Cruz Biotech-
nology) was used. For detection of phosphorylated
AQP2 a phosphorylation sensitive rabbit p-AQP2 anti-
body (1:1,000, KO307, kindly provided by Professor
Søren Nielsen, Department of Biomedicine, Aarhus Uni-
versity, Denmark) was applied. As a loading control,
polyclonal rabbit antibodies against ß-actin (1:10,000,
catalog number 8227-50, Abcam, Cambrigde, MA, USA)
were used. Detection was performed using secondary
horseradish peroxidase (HRP) conjugated polyclonal
rabbit anti-goat and polyclonal goat anti-rabbit HRP
conjugated antibodies (1:10.000, catalog numbers P0449
and P0448, Dako). All antibodies were diluted in TBS-T
(0.9 % NaCl, 20 mM Tris-HCl added 0.1 % Tween 20
(Sigma)). For visualization SuperSignal West Dura Ex-
tended Duration Substrate (Thermo Scientific, Waltham,
MA, USA) and ImageQuant Las4000 digital imaging
system (GE Healthcare, Cleveland, OH, USA) were used.
The cellular experiments were replicated minimum
three times unless otherwise stated.
Results
Clinical data indicate partial CNDI
A Swedish family including four family members with
symptoms of DI was investigated (Fig. 1). The proband
(subject IV-2) was first admitted to hospital at nine
months of age, presenting with polydipsia, polyuria and
signs of failure to thrive. The extremely high fluid intake
of 200 ml/kg bw/24 h of the proband reported by the
parents and very low basal urine osmolality on two occa-
sions strongly suggested the diagnosis of DI. Testing of
the proband upon admission revealed a low spot urine
osmolality of 122 mOsm/kg and a normal plasma osmo-
lality of 278 mOsm/kg. Treatment of the proband with
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2.5 μg intranasal dDAVP once daily led to no improve-
ment of thirst and urine output. The father of the pro-
band was initially suspected to suffer from familial
neurohypophyseal DI (FNDI), as he was responding to
dDAVP treatment.
A water deprivation test (WDT) was performed in
the proband (Table 1) at the age of 21 months. Prior to
WDT her basal urine osmolality was 32 mOsm/kg,
while plasma sodium (137 mmol/L) and osmolality
(286 mOsm/kg) was within control range. Plasma AVP
was slightly elevated (2.3 pg/mL) considering the
plasma osmolality level. After six hours of thirst the
urine osmolality increased to 268 mOsm/kg, plasma so-
dium to 139 mmol/L, plasma osmolality to 295 mOsm/
kg and plasma AVP displayed a 2.4 fold increase (from
1.3 to 3.1 pg/mL) and body weight was reduced by
3.7 % (Table 1). The father was likewise subjected to a
WDT (Table 2). Prior to water restriction his urine
osmolality was 126 mOsm/kg and plasma osmolality
was 290 mOsm/kg. After WDT the osmolality reached
613 mOsm/kg and plasma osmolality 303 mOsm/kg,
respectively. By increasing the dose of dDAVP given to
the proband gradually to 40 μg three times daily, symp-
toms of DI were alleviated for 4-5 h with subsequent
improvement of sleep and well-being.
Since the plasma osmolality of the proband did not
exceed 300 mOsm/L before termination of the WDT
test and no additional clinical examinations have been
achievable since then, the differential diagnosis remains
unclear. The relatively high level of plasma AVP under
basal conditions (2.3 pmol/mL) seen in the proband
together with a normal AVP response to dehydration as
well as only partial alleviation of symptoms using high
doses of dDAVP, indicates segregation of a partial
nephrogenic DI phenotype (CNDI) in the family.
DNA sequence analysis revealed a novel variation in the
AQP2 gene
In order to confirm the diagnosis and specifically iden-
tify its genetic cause, molecular genetic analysis was
performed in the two affected subjects as well as in two
unaffected family members (subject III-3 and IV-1,
Fig. 1). DNA sequencing analysis of the coding regions
of the AQP2 gene in the proband (subject IV-2) revealed
a novel g.4807C > T variation in exon 4 in one allele of
the gene (number refer to the genomic DNA sequence
of the AQP2 gene, GenBank accession number P41181)
(Fig. 2a). The identified variation is predicted to change
codon 254 of the AQP2 mRNA from CGG to UGG
resulting in an arginine to tryptophan substitution
(p.R254W) in the C-terminal of AQP2. No other
sequence variations were found in the coding regions of
the AQP2 gene. An identical genotype was identified in
the probands farther (subject III-2). The unaffected
subjects (III-3 and IV-1) were both homozygous for the
normal allele. Similarly, an unrelated control subject
(unaffected) was homozygous for the normal allele
(Fig. 2b). Common variations at this position were
neither identified by sequence analysis of 100 alleles
from healthy Danish individuals nor in the 1000 Ge-
nomes database (http://www.1000genomes.org/). DNA
sequencing analysis of the coding regions of the AVP
Fig. 1 Pedigree showing a Swedish family with autosomal dominant
inheritance of congenital nephrogenic diabetes insipidus. The affected
individuals are illustrated with filled symbols. Asterisks indicate the
members of the family who were genetically tested. The proband is
marked with an arrow











Night before WDT 9120 44 292 133 2.3
Morning before
WDT
8930 32 286 137 1.3
During WDT 54 3.2
After WDT 8600 268 295 139 3.1
WDT water deprivation test
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gene in the proband did not reveal any variations. Over-
all, these data strongly indicate that the affected subjects
suffer from partial CNDI due to heterozygosity for the
p.R254W substitution in AQP2.
Verification of transduction capacity of the LV vector in
MDCK cells
The identified variation results in an amino acid substi-
tution in the C-terminal tail of the protein, suggesting
altered trafficking of AQP2 [24]. Thus, to investigate the
cellular handling of AQP2-R254W we designed and
purified lentivirus (LV) vectors containing the AQP2
c.760C > T cDNA or the AQP2 WT gene driven by a
phosphoglycerate kinase (PGK) promoter (Fig. 3a). The
resulting LV vector constructs encodes AQP2-R254W or
AQP2-WT proteins. Other variations in codon 254 of
the AQP2 mRNA, likewise resulting in amino-acid
changes such as the AQP2-Arg254Leu (AQP2-R254L)
substitution, have been described to affect Ser256
phosphorylation and intracellular trafficking of AQP2
[14, 15]. Thus, LVs expressing AQP2-R254L were
included as a positive control for impaired phosphoryl-
ation and defective intracellular trafficking [14]. To
confirm functionality and the capacity of the LV vector
to transduce MDCK cells, we initially delivered vectors
encoding AQP2-WT and collected data by immuno-
staining and CLSM analysis (Fig. 3b and c). The cells
were stained with an antibody directed against AQP2 as
well as an antibody labeling tight junctions (ZO-1), the
boundary between apical and basolateral membrane
domains. Sustained expression of AQP2-WT protein,
solely displaying an intracellular staining pattern without
any AQP2-specific staining of the plasma membrane,
was evident in unstimulated cells (Fig. 3b, Control).
Upon stimulation with forskolin, an adenylyl cyclase
activator that mimics the action of AVP by increasing
the intracellular level of cAMP, the localization of
AQP2-WT protein was clearly shifted from cytoplasmic
vesicles to the cell membrane (compare Fig. 3b and c).
Impaired intracellular trafficking of AQP2-R254W
Having verified that the LV vector results in sustained
expression and translocation of AQP2-WT from intra-
cellular sites to the cell membrane upon forskolin stimu-
lation, we generated by means of puromycin selection
three MDCK cell lines stably expressing AQP2-WT,
AQP2-R254W and AQP2-R254L proteins. Untransduced
MDCK cells were used as negative controls in subse-
quent experiments. In contrast to AQP2-WT, almost all
of the detected AQP2-R254W protein was intracellularly
retained upon forskolin stimulation (compare Fig. 4a-c
with 4d-f ). Only very weak AQP2-specific staining at the
plasma membrane was observed and the majority of
AQP2-R254W protein was localized in the cytoplasm,
concentrated in the perinuclear space (Fig. 4d-f ). Similar
results were obtained when analyzing the cellular fate of
the AQP2-R254L protein (Fig. 4g-i). These observations
clearly suggest that the trafficking of AQP2-R254W, like
AQP2-R254L, is impaired, resulting in intracellular accu-
mulation of variant protein.
Phosphorylation of S256 is inhibited in AQP2-R254W
Given that the AQP2-R254W substitution disrupts a
canonical and crucial PKA consensus site in AQP2 it is
obvious to hypothesize that the impairment in trafficking
described above is caused by impaired phosphorylation





Before WDT 126 290
After WDT 613 303
WDT water deprivation test
A
B
Fig. 2 Identification of a novel AQP2 variation in affected individuals.
Direct DNA sequence analysis of the coding regions of the AQP2
gene in: (a) subject IV-2 and (b) an unaffected control subject. Data
from both the sense and anti-sense strands corresponding to
genomic region g.4801–4815 within exon 4 of the AQP2 gene are
shown (numbers refer to the genomic DNA sequence of the AQP2
gene, GenBank accession number P41181). The affected subject IV-2
is heterozygous for a single base substitution (g.4807C > T) resulting
in a double peak in the electropherogram (arrow). The amino acid
residues encoded by these sequences are shown above using
three-letter abbreviations
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at S256 as it has been described for other R254 substitu-
tions previously [14, 15, 25]. Thus, we investigated phos-
phorylation at S256 by means of Western blotting
analysis using an antibody directed against S256 pho-
phorylated AQP2 [4, 11]. Extracts from the MDCK cells
(AQP2-WT, AQP2-R254W and AQP2-R254L) incubated
with or without forskolin were subjected to the analysis
(Fig. 5). Under both conditions the phospho-sensitive
antibody detected a prominent band with an apparent
mobility of approximately 26 kDa in extracts from cells
expressing AQP2-WT corresponding to the expected
mobility of unglycosylated AQP2 (Fig. 5b, lane 1 and 2).
Even though similar levels of total AQP2-WT protein
were observed with or without forskolin treatment, the
level of phosphorylated AQP2 (p-AQP2) WT protein
identified in unstimulated cells (Fig. 5c, lane 7 and 8)
seemed higher compared to the level in forskolin stimu-
lated cells (Fig. 5b, lane 1 and 2). Since forskolin is ex-
pected to increase phosphorylation of AQP2, this
finding could reflect that the amount of detectable p-
AQP2-WT in Western blotting analysis depends on the
cellular localization of the protein. As shown in Fig. 3
AQP2-WT rapidly accumulates in the plasma membrane
following stimulation, thereby resulting in a possible
lower amount of extractable p-AQP2-WT following cell
lysis, compared to the situation in unstimulated cells, in
which p-AQP2-WT solely is localized intracellularly.
Two faint p-AQP2-specific bands with a higher mobil-
ity, probably representing AQP2 with complex glyco-
sylations were also recognized in the samples
(indicated by asterisks in Fig. 5b, lane 1 and 2). Inter-
estingly, no p-AQP2-specific bands could be recog-
nized in extracts from cells expressing AQP2-R252W
(Fig. 5b, lane 3 and 4) even though almost identical
amounts of ß-actin (Fig. 5a) and total AQP2 protein
(Fig. 5c) were present in the extracts from cells expressing
AQP2-WT and AQP2-R254W, respectively. Similar re-
sults were obtained in the extracts from cells expressing
AQP2-R254L (Fig. 5b, lane 5 and 6), suggesting that phos-
phorylation at S256 is inhibited in the AQP2-R254W
protein as it is in the AQP2-R254L protein.
Defective insertion of AQP2-R254W in the apical
membrane
AQP2 shuttles between subapical vesicles and the
plasma membrane, and phosphorylation at S256 is ne-
cessary for plasma membrane accumulation. However,
when endocytosis was blocked by expression of a
GTPase-deficient dynamin-2 mutant, Dyn2-K44A, both
AQP2-WT and an S256 phosphorylation-deficient
mutant AQP2 mutant, AQP2-S256A, accumulated in
the plasma membrane in unstimulated cells [8], showing
that the S256 phosphorylation is required for regulated
AVP/cAMP-mediated translocation of AQP2 to the
A
B C
Fig. 3 Localization of AQP2-WT in MDCK cells under unstimulated and forskolin stimulated conditions. MDCK cells transduced with LVs containing the
AQP2-WT gene for stably expression of AQP2-WT were incubated with 150 μM forskolin prior to immunostaining for AQP2 and tight junctions, ZO-1. The
cells were then subjected to CLSM analysis. (a) Schematic representation of the utilized LV expression cassette. The LV transfer vector incorporates a PGK
promoter that drives the expression of a single mRNA encoding both AQP2 and puromycin. (b) Unstimulated MDCK cells expressing AQP2-WT. (c) AQP2-
WT in MDCK cells after forskolin stimulation. Scale bars = 20 μm. CMV, cytomegalovirus; cPPT, central polypurine tract; LTR, long terminal repeat; PGK, phos-
phoglycerate kinase 1 promoter; ψ, packaging signal; RRE, Rev-responsive element; U3 (SIN), Self-inactivating deletion in the U3 region; WPRE, woodchuck
hepatitis virus post-transcriptional regulatory element

























































Fig. 5 Analysis of the phosphorylation level of AQP2-WT, AQP2-R254W and AQP2-R254L in MDCK cells by means of Western blotting analysis.
MDCK cells stably expressing AQP2 variant proteins were incubated with (150 μM) and without forskolin (+/-) for one hour. Following harvest and
lysis, cell extract were subjected to SDS-PAGE and proteins were subsequently transferred to a PVDF membrane as described in Methods. Lanes 1,
2, 7 and 8: AQP2-WT; lanes 3, 4, 9 and 10: AQP2-R254W; lanes 5, 6, 11 and 12: AQP2-R254L. Following transfer, the membrane was cut in three
separate pieces as indicated by the dotted lines and used for individual immunostaining analysis (a-c). (a) Loading control using an anti-ß-actin
antibody. (b) AQP2 protein with S256 phosphorylation detected by a phosphor-sensitive anti-AQP2 antibody. The two asterisks denote p-AQP2-
specific bands with an apparant higher mobility compared to the expected size of approximately 26 kDa. (c) Total amount of AQP2 protein as
detected by an anti-AQP2 antibody. A molecular marker is indicated on the left (kDa). The presented Western blot represents the results obtained
in two independent experiments
Fig. 4 Localization analysis of AQP2-WT, AQP2-R254W and AQP2-R254L in MDCK cells under forskolin stimulated conditions. MDCK cells stably expressing
AQP2-WT, AQP2-R254W or AQP2-R254L were incubated with 150 μM forskolin prior to immunostaining for AQP2 and tight junctions, ZO-1. The cells were
then subjected to CLSM analysis. (a,d,g) Inverted contrast images of AQP2 labeling in AQP2-WT, AQP2-R254W or AQP2-R254L expressing cells. (b,e,h)
Inverted contrast illustrations of ZO-1 expression, as detected by an anti-ZO-1 antibody, in the MDCK cells shown in a, d and g. (c,f,i) Merged color
illustrations of the images shown in a-b, d-e and g-h, respectively. Scale bars = 20 μm
Dollerup et al. BMC Nephrology  (2015) 16:217 Page 8 of 12
plasma membrane but not shuttling. So although AQP2-
R254W could not be phosphorylated, it may still be able
to shuttle to the plasma membrane. To test this, we tran-
siently transfected either dynamin-2 WT (Dyn2-WT) or
the dominant-negative Dyn2-K44A GFP-fusion-proteins
into the MDCK cells stably expressing AQP2-WT and
AQP2-R254W, respectively. As expected, AQP2-WT and
AQP2-R254W proteins were exclusively found in intracel-
lular vesicles upon co-expression of Dyn2-WT-GFP
(Fig. 6a and c), suggesting that the majority of AQP2 is
localized intracellularly at steady state in unstimulated
cells. When AQP2-WT cells were co-transfected with the
Dyn2-K44A-GFP construct, AQP2-WT localized to the
plasma membrane in the absence of forskolin stimulation
(Fig. 6b). This was in contrast to AQP2-R254W, which
remained intracellularly localized despite over-expression
of Dyn2-K44A-GFP with no or very low levels of AQP2-
R254W observed in the plasma membrane. This indicates
that the substitution of AQP2-arginine-254 to tryptophan
inhibits both phosphorylation at serine-256 but also re-
cruitment of AQP2-R254W to subapical vesicles (Fig. 6d).
AQP2-R254W is not localized in late endosomes
Our presented data revealed that AQP2-R254W, similar
to AQP2-R254L remains localized in intracellular vesi-
cles upon forskolin stimulation (Figs. 3 and 4) and that
the vesicles were unable to reach the plasma membrane
during expression of dominant-negative dynamin 2
(Fig. 6). To determine whether these vesicles could be
related to the endocytotic pathway, co-localization ana-
lysis using GFP-tagged Rab7 and Rab9, was performed.
Rab7 is implicated in the transport from early to late
endosomes [21], whereas Rab9 functions in the transport
between late endosomes and the trans Golgi network
[22]. Following transfection with plasmid DNA encoding
either Rab7-GFP or Rab9-GFP fusion proteins, the
AQP2-expressing MDCK cells were labeled with anti-
AQP2 antibodies. AQP2 and Rab7-GFP/Rab9-GFP
expression was inspected by CLSM. The majority of the
AQP2-WT protein was situated in Rab7-GFP negative
and Rab9-GFP negative intracellular vesicles, but some
co-localization of AQP2-WT and Rab7-GFP and Rab9-
GFP was observed (Fig. 7a-c and Additional file 1 A-C).
Interestingly, the majority of AQP2-R254W and AQP2-
R254L proteins did not co-localize with Rab7-GFP posi-
tive endosomes, suggesting that AQP2-R254W does not
accumulate in endosomes to any high extent, but rather
in another compartment. This indicates that AQP2-
R254W may follow a different post-translational route
than AQP2-WT and that the majority of AQP2-R254W
does not reach sub-apical vesicles and the plasma
membrane.
Discussion
Partial phenotype in CNDI
Clinical studies of the proband suggest that AQP2-
R254W is associated with a partial nephrogenic DI
phenotype with some ability to concentrate urine when
dehydrated. This finding may thus support the notion
that substitutions affecting AQP2-R254, including AQ
P2-R254L and AQP2-R254Q, causes partial nephrogenic
DI [25]. During WDT her plasma AVP increased from
1.3 to 3.1 pg/mL as a response to the developing dehy-
dration. Concomitantly, the urine osmolality increased
significantly from 32 to 268 mOsm/kg, albeit with an
endpoint slightly below 300 mOsm/kg normally used in
the definition of partial DI in adults [25]. It is well
known that children below 2 years of age have not yet
developed a normal urine concentration capacity. The
father of the proband showed an increase in urine osmo-
lality from 126 to 613 mOsm/kg during WDT. The
father was initially suspected for FNDI, which is not
unusual when patients with partial CNDI are able to
concentrate urine to some degree [26], and additionally
respond to dDAVP in high doses. To initiate the right
treatment, establishment of the correct diagnose is
important. Genetic testing of patients with a family his-
tory of DI, as performed in the present study, is often a
helpful tool and should therefore be considered. This is
particularly important in the case of affected infants,
Fig. 6 Investigation of the recycling process of AQP2 by inhibition
of endocytosis via GTPase-deficient dynamin-2 mutation (K44A) in
transiently transfected, unstimulated MDCK-AQP2 cells. The MDCK
cells stably expressing AQP2-WT or AQP2-R254W were transiently
transfected with plasmid DNA encoding GFP-tagged dynamin-2,
either Dyn2-WT (a,c) or Dyn2-K44A (b,d). Two days post-transfection
the cells were immunostained with AQP2-sensitive antibody and
subjected to confocal laser scanning microscopy. Note the AQP2 staining
of the plasma membrane in cells expressing AQP2-WT indicated with an
arrow (b). The presented data represents the results obtained in two
independent experiments. Scale bars = 20 μm
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since early diagnose might prevent dehydration episodes
and related complications, such as growth retardation,
cerebral damage, seizures and even death.
AQP2-R254W causes CNDI by disabling insertion in
subapical vesicles and phosphorylation at S256
The use of a phosphorylation sensitive antibody clearly
demonstrated that phosphorylated AQP2 is only observed
in MDCK cells expressing AQP2-WT, whereas AQP2-
R254W and AQP2-R254L remained unphosphorylated in
both unstimulated and forskolin stimulated cells. This
indicated that phosphorylation of S256 is disabled in
AQP2-R254W, similarly to AQP2-R254L. Since the R254-
residue is part of the PKA consensus site (R-R254-X-S),
substitution of arginine-254 with tryptophan most prob-
ably impairs phosphorylation at S256, similarly to what is
observed for other AQP2 variations affecting the R254-
residue [14, 15]. Blocking internalization with Dyn2-K4
4A-GFP resulted in accumulation of AQP2-WT in the
plasma membrane as previously observed [27], whereas
the AQP2-R254W remained localized in intracellular
vesicles. This experiment demonstrated that the vast
majority of AQP2-R254W does not reach the plasma
membrane, and suggests that the trafficking of AQP2-
R254W is affected prior to the point of sub-apical vesicle
formation. As a consequence the recycling of AQP2-
R254W to and from the plasma membrane is disturbed.
The majority of AQP2-R254W was retained in intracellu-
lar vesicles located in the perinuclear space. Analysis of
co-localization with two different late endosome markers
(Rab7-GFP and Rab9-GFP) revealed some overlap with
AQP2-WT, whereas AQP2-R254W and AQP2-R254L pri-
marily co-localize with Rab7-GFP and Rab9-GFP negative
endosomes, suggesting that AQP2 R254W and AQP2-
R254L, in opposite to AQP2-R254Q [15] are not, or at
least to a very low extend, internalized by endocytosis.
The proband and her father in this study are heterozy-
gous for the AQP2 variant allele, implying simultaneous
synthesis of AQP2-WT and AQP2-R254W proteins in
the cells of the collecting ducts. If we hypothesize that
the tetramerization of AQP2 is random, some of the
formed tetramers will consist of three or four AQP2-
WT monomers, and hence be able to be sufficiently
phosphorylated at S256 in order to undergo normal
trafficking and insertion in the plasma membrane as
fully functional water channels [9, 10]. This notion may
thus explain their ability to concentrate the urine in
response to high levels of dDAVP following medical
Fig. 7 Co-localization analysis of AQP2 proteins and Rab7 positive late endosomes in unstimulated cells. MDCK cells stably expressing AQP2-WT,
AQP2-R254W or AQP2-R254L were transiently transfected with plasmid DNA encoding Rab7-GFP as a marker for late endosomes. Two days post-
transfection the cells were immunostained with an AQP2-sensitive antibody and subjected to confocal laser scanning microscopy. (a,d,g) Inverted
contrast images of AQP2 labeling in AQP2-WT, AQP2-R254W or AQP2-R254L expressing cells. (b,e,h) Inverted contrast illustrations of the Rab7-GFP
expression in the MDCK cells shown in a, d and g. (c,f,g) Merged color illustrations of the images shown in a-b, d-e and g-h, respectively. Arrows
in a and b illustrates examples of co-localization of AQP2-WT and late endosomes. The presented data represents the results obtained in two in-
dependent experiments. Scale bars = 20 μm
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treatment. The small percentage of published CNDI
cases with autosomal dominant inheritance of the condi-
tion are all due to variations affecting the C-terminal tail
of AQP2 [1], either by amino acid substitutions or by
frame shift. The pathological effects of these variations
seem to include defective trafficking, such as retention
in the Golgi apparatus [18], misrouting of AQP2 to the
basolateral membrane [16], sorting of AQP2 to the to
late endosomes or lysosomes [28], or defective phos-
phorylation of AQP2-S256 [14], suggesting that the vari-
ations act by a dominant negative mechanism. Indeed,
our findings, showing that AQP2-R254W most likely
causes partial CNDI in the studied Swedish family by
disabling AQP2-R254W from reaching the plasma mem-
brane to facilitate AVP mediated urine concentration,
supports these data. Furthermore, the presented data
may also contribute to the understanding why the condi-
tion is usually only partial.
Conclusions
In conclusion, this study demonstrates defective traffick-
ing of AQP2-R254W protein to the cell surface by
disabled AQP2-R254W incorporation into subapical
vesicles as well as impaired phosphorylation at S256,
rendering the AQP2-R254W protein predominantly to
be localized in intracellular vesicles likely different from
late endosomes. Studies involving pharmacological chap-
erones have shown some effect on retained V2 receptor
variants in cells [29] and displayed beneficial effects in
patients [30] whereas treatments targeting phosphoryl-
ation and trafficking defective AQP2, like AQP2-
R254W, remain to be explored. The finding that the
novel AQP2 variation causes partial CNDI in the studied
Swedish family by such a mechanism might direct stud-
ies aiming to identify new treatments in autosomal dom-
inant CNDI.
Additional file
Additional file 1: Co-localization analysis using GFP-tagged Rab9
for labeling of late endosomes in unstimulated cells. MDCK cells
stably expressing AQP2-WT, AQP2-R254W or AQP2-R254L were transiently
transfected with plasmid DNA encoding Rab9-GFP as a marker for late
endosomes. Two day post transfection the cells were immunostained
with an AQP2-sensitive antibody and subsequently analyzed by confocal laser
scanning microscopy. (A,D,G) Inverted contrast images of AQP2 labeling in
cells expressing AQP2-WT, AQP2-R254W or AQP2-R254L. (B,E,H) Inverted
contrast illustrations of Rab9-GFP in the MDCK cells shown in A, D and G.
(C,F,G) Merged color illustrations of the images shown in A-B, D-E and G-H,
respectively. Arrows in A and B illustrates examples of co-localization of AQP2-
WT and late endosomes. The presented data represents the results obtained
in two independent experiments. Scale bars = 20 μm. (PDF 468 kb)
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